Experience of rofecoxib in patients with osteoarthritis previously treated with traditional non-steroidal anti-inflammatory drugs in Spain: Results of phase 2 of the VICOXX study

Current Medical Research and Opinion

Volumn 19, Issue 4, 2003, Pages 288-297

  Arboleya, Luis R ^a,d   De la Fiquera, Enrique ^b   García, María Soledad ^c   Aragón, Belén ^c  

^a HOSPITAL DE CABUEÑES   (Spain)

^b CENTRO DE SALUD DELICIAS SUR   (Spain)

^c Chiltern International ^*  (Spain)

^d Seccion de Reumatologia   (Spain)

Author keywords

Effectiveness; NSAID; Osteoarthritis; Rofecoxib; Tolerability

Indexed keywords

ACECLOFENAC; ACETYLSALICYLIC ACID; ANALGESIC AGENT; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; FLURBIPROFEN; GLUCOSAMINE; IBUPROFEN; INDOMETACIN; KETOPROFEN; MELOXICAM; NABUMETONE; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; ROFECOXIB; TENOXICAM;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG UTILIZATION; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; FOLLOW UP; GASTRODUODENAL ULCER; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; HEALTH STATUS; HEMATEMESIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA AND VOMITING; OSTEOARTHRITIS; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PATIENT SATISFACTION; PHASE 2 CLINICAL TRIAL; PHYSICIAN ATTITUDE; PRESCRIPTION; PRIMARY MEDICAL CARE; PROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; SCORING SYSTEM; SPAIN; STOMACH PROTECTION; SYMPTOM;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; DYSPEPSIA; HUMANS; LACTONES; MIDDLE AGED; OSTEOARTHRITIS; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; QUESTIONNAIRES; SULFONES; TREATMENT OUTCOME;

EID: 0037667412     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079903125001910     Document Type: Article

References (19)

1. Arboleya LR, de la Figuera S, García MS, Aragón B, and the VICOXX Study Group. Management pattern for patients with osteoarthritis treated with traditional non-steroidal anti-inflammatory drugs in Spain prior to introduction of Coxibs. Curr Med Res Opin 2003;19(4):278-287
2. Dolce JJ, Crisp C, Manzella B, Richards JM, Hardin M, Bailey WC. Medication adherence patterns in chronic obstructive pulmonary disease. Chest 1991;99:837-41
3. Watson DJ, Harper SE, Zhao P-L, Quan H, Bolognese JA, Simon TJ. Gastrointestinal tolerability of the selective cyclooxygenase inhibitor rofecoxib compared with non-selective COX-I and COX-2 inhibitors in osteoarthritis. Arch Intern Med 2000;160:2998-3003
4. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-8
5. Lanas A. Cost stratification of nonsteroidal anti-inflammatory drug-associated gastrointestinal side effects [Spanish]. Med Clin (Barc) 2000;114(Suppl 3):46-53
6. Schnitzer TJ. Use of nonsteroidal anti-inflammatory drugs and gastroprotective agents before the advent of cyclooxygenase-2-selective inhibitors: analysis of a large United States claims database. Clin Ther 2001;23:1984-98
7. Johnson RE, Hornbrook MC, Hooker RS, Woodson GT, Schneidman R. Analysis of the costs of NSAID-associated gastropathy: experience in a US health maintenance organization. Pharmacoeconomics 1997;12:76-88
8. Moore RA. The hidden costs of arthritis treatment and the cost of new therapy - the burden of non-steroidal anti-inflammatory drug gastropathy. Rheumatology 2002;41 (Suppl 1):7-15
9. Fendrick AM. Developing an economic rationale for the use of selective COX-2 inhibitors or patients at risk for NSAID gastropathy. Cleve Clin Med J 2002;69(Suppl 1):S159-S164
10. Laine L, Bombardier C, Ramey DR, Watson DJ, Pellisier JM, Reicib A. Less use of gastrointestinal (GI) protective agents and GI-related procedures with rofecoxib vs. naproxen in the VIGOR (VIOXX GI Outcomes Research) Study. Ann Rheum Dis 2001;60(Suppl 1):278 (abstract)
11. Russo P, Capone A, Attanasio E, et al. Pharmacoutilisation and costs of osteoarthritis: changes induced by the introduction of a cyclooxygenase-2 inhibitor into clinical practice. Rheumatology 2003; March 31 (epub ahead of print)
12. Weaver AL. Rofecoxib: clinical pharmacology and clinical experience. Clin Ther 2001;23:1323-38
13. Ehrich EE, Schnitzer TJ, Mcllwain H, et al. for the Rofecoxib Osteoarthritis Pilot Study Group. Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week, double blind, placebo controlled pilot study of rofecoxib. J Rheumatol 1999;26:2438-47
14. Cannon GW, Caldwell JR, Holt P, et al. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium. Results of a one-year, randomized clinical trial in patients with osteoarthritis of the hip and knee. Arthritis Rheum 2000;43:978-87
15. Day R, Morrison B, Luza-Castenada O, et al. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Arch Intern Med 2000;160:1781-7
16. Truitt KE, Sperling RS, Ettinger Jr WH, et al. for the Phase III Rofecoxib Geriatric Study Group. A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients with osteoarthritis. Aging Clin Exp Res 2001;13:112-21
17. Geba GP, Weaver AL, Polis AB, Dixon ME, Schnitzer TJ, for the VACT Group. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial. JAMA 2002;287:64-71
18. Steinfeld S, Poriau S. Patient and physician satisfaction with rofecoxib in osteoarthritis: results of the EVA survey. Cur Med Res Opin 2001;17:1-7
19. Zacher J, Schattenkirchner M. Patient and physician satisfaction with rofecoxib in osteoarthritis: results of a post-marketing surveillance study in primary care in Germany. Curr Med Res Opin 2002;18:229-36